Atossa Genetics Inc. (ATOS): Price and Financial Metrics

Atossa Genetics Inc. (ATOS): $1.34

0.02 (-1.47%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ATOS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#145 of 340

in industry

ATOS Price/Volume Stats

Current price $1.34 52-week high $2.31
Prev. close $1.36 52-week low $0.62
Day low $1.31 Volume 683,900
Day high $1.38 Avg. volume 1,374,032
50-day MA $1.32 Dividend yield N/A
200-day MA $1.10 Market Cap 168.51M

ATOS Stock Price Chart Interactive Chart >


Atossa Genetics Inc. (ATOS) Company Bio


Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.


ATOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ATOS Latest Social Stream


Loading social stream, please wait...

View Full ATOS Social Stream

Latest ATOS News From Around the Web

Below are the latest news stories about ATOSSA THERAPEUTICS INC that investors may wish to consider to help them evaluate ATOS as an investment opportunity.

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

Here is how Atossa Genetics Inc. (ATOS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Yahoo | December 8, 2023

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the appointment of Dr. Arezoo Mirad as Senior Medical Director. “We are excited to welcome Dr. Mirad to Atossa and look forward to leveraging her extensive experience in the clinical development of oncology candidates to further accelerat

Yahoo | December 4, 2023

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that it has reached full enrollment in the Company’s Karisma-Endoxifen clinical trial, the 240-person Phase 2 study investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). Participants have be

Yahoo | November 20, 2023

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Achieved significant enrollment milestones in ongoing Phase 2 clinical trialsFour ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS Ended third quarter 2023 with $94.0 million of cash and cash equivalents SEATTLE, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, to

Yahoo | November 13, 2023

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Jonathan Finn, CFA, has been appointed to Atossa’s board of directors, effective November 8, 2023. Mr. Finn has more than 25 years of experience in the financial industry with a focus on early to mid-stage biotech and technology comp

Yahoo | November 9, 2023

Read More 'ATOS' Stories Here

ATOS Price Returns

1-mo 20.72%
3-mo -2.19%
6-mo 64.01%
1-year 18.58%
3-year -68.40%
5-year -34.31%
YTD 52.27%
2023 66.51%
2022 -66.97%
2021 68.42%
2020 -39.49%
2019 53.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!